Article
Klebsiella pneumoniae Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from β-Lactamase Protein Engineering.
mBio - 31 Oct 2017
Barnes Melissa D, Winkler Marisa L, Taracila Magdalena A, Page Malcolm G, Desarbre Eric, Kreiswirth Barry N, Shields Ryan K, Nguyen Minh-Hong, Clancy Cornelius, Spellberg Brad, Papp-Wallace Krisztina M, Bonomo Robert A
Abstract excerpt
The emergence of Klebsiella pneumoniae carbapenemases (KPCs), β-lactamases that inactivate "last-line" antibiotics such as imipenem, represents a major challenge to contemporary antibiotic therapies. The combination of ceftazidime (CAZ) and avibactam (AVI), a potent β-lactamase inhibitor, represents an attempt to overcome this formidable threat and to restore the efficacy of the antibiotic against Gram-negative...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.